Spyropoulos, Alex C.  <br/><br/>
Advanced Therapy for Intermediate-Risk Pulmonary Embolism 

 - páginas: 2052-2054 
<br/><br/> Pulmonary embolism is the third leading cardiovascular cause of complications and death after myocardial infarction and stroke, with a rising incidence globally. The approach to management of acute pulmonary embolism as a condition to be treated nonsurgically with systemic heparin anticoagulation was established more than 60 years ago. Patients with high-risk pulmonary embolism and cardiogenic shock appear to benefit from early thrombus removal, with rapid reductions in pulmonary obstruction and pulmonary vascular resistance from baseline and a lower risk of death than with anticoagulation alone, but at the cost of a nearly 10% risk of major bleeding. 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ANTICOAGULACIÓN<br/>TROMBOEMBOLISMO <br/>CARDIOLOGÍA<br/>NEUMOLOGÍA<br/>MEDICINA CLÍNICA HOSPITALARIA<br/>RADIOLOGÍA GENERAL